Sanofi’s mRNA COVID-19 vaccine candidate not ready this year – CEO By Reuters – Investing.com UK

PARIS (Reuters) – A COVID-19 vaccine candidate developed by Sanofi (PA:SASY) and U.S. group Translate Bio “will not be ready this year,” the French drugmaker’s chief executive told Le Journal du Dimanche newspaper.
Clinical trials of this vaccine, which will be based on a technology known as mRNA — on which lean approved vaccines of Pfizer/BioNTech and Moderna (NASDAQ:MRNA) –, are expected to start this quarter.
In December last year, Sanofi had said it was targeting “earliest potential approval”…

Click here to view the original article.